**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Zhiyang A. Wei, Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Brigham and Women's Hospital, Boston, MA.

**Main Body of the Abstract**
Background 
Characterization of light-chain (AL) and transthyretin (ATTR) amyloid deposits in the heart and systemic organs is currently challenging. This study evaluates the novel PET radiotracer 124I-evuzamitide for quantifying AL and ATTR amyloid burden in the heart and systemic organs.
Methods
The study included 24 patients (12 AL, 12 ATTR) and 16 healthy controls who underwent 124I-evuzamitide PET/CT at 5 hours post-injection (median 0.98 mCi). The liver, spleen, kidneys, heart, pancreas, and adrenal glands were automatically segmented using a trained deep learning algorithm (AIQ Solutions). Mean standardized uptake value (SUV) in each organ was normalized by the average aortic arch uptake to obtain ratio SUVR measurements. Abnormal uptake was defined as mean+1.96SD in the controls.
Results 
124I-evuzamitide demonstrated excellent sensitivity in detecting cardiac amyloidosis, identifying 24/24 patients. It also identified abnormal uptake in the liver (3/12 AL and 1/12 ATTR), spleen (5/12 AL), kidneys (4/12 AL), pancreas (7/12 AL), and adrenal glands (6/12 AL and 1/12 ATTR) (Table 1). Compared to the International Society of Amyloidosis criteria for organ involvement in AL, 124I-evuzamitide identified more patients with hepatic involvement and fewer patients with renal involvement (2/5, 40%). Notably, it detected abnormal renal uptake in two patients without biochemical signs of renal involvement. The novel findings of abnormal pancreatic and adrenal uptake indicate 124I-evuzamitide's potential for early amyloidosis detection in these organs.
Conclusions
124I-evuzamitide PET/CT is highly sensitive for detecting amyloid deposits in the heart and systemic organs, providing a novel noninvasive approach for characterizing cardiac and systemic organ amyloid burden.



Automatic quantification of AL and ATTR amyloidosis disease burden using 124I-evuzamitide, a novel radiotracer PB120 (#416)

We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.